Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Author:

Zhou Jian,Sun Huichuan,Wang Zheng,Cong Wenming,Wang Jianhua,Zeng Mengsu,Zhou Weiping,Bie Ping,Liu Lianxin,Wen Tianfu,Han Guohong,Wang Maoqiang,Liu Ruibao,Lu Ligong,Ren Zhengang,Chen Minshan,Zeng Zhaochong,Liang Ping,Liang Changhong,Chen Min,Yan Fuhua,Wang Wenping,Ji Yuan,Yun Jingping,Cai Dingfang,Chen Yongjun,Cheng Wenwu,Cheng Shuqun,Dai Chaoliu,Guo Wenzhi,Hua Baojin,Huang Xiaowu,Jia Weidong,Li Yaming,Li Yexiong,Liang Jun,Liu Tianshu,Lv Guoyue,Mao Yilei,Peng Tao,Ren Weixin,Shi Hongcheng,Shi Guoming,Tao Kaishan,Wang Wentao,Wang Xiaoying,Wang Zhiming,Xiang Bangde,Xing Baocai,Xu Jianming,Yang Jiamei,Yang Jianyong,Yang Yefa,Yang Yunke,Ye Shenglong,Yin Zhengyu,Zhang Bixiang,Zhang Boheng,Zhang Leida,Zhang Shuijun,Zhang Ti,Zhao Yongfu,Zheng Honggang,Zhu Jiye,Zhu Kangshun,Liu Rong,Shi Yinghong,Xiao Yongsheng,Dai Zhi,Teng Gaojun,Cai Jianqiang,Wang Weilin,Cai Xiujun,Li Qiang,Shen Feng,Qin Shukui,Dong Jiahong,Fan Jia

Abstract

<b><i>Background:</i></b> Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. <b><i>Summary:</i></b> Since the publication of <i>Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition)</i> in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition <i>(2019 Edition)</i> was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. <b><i>Key Messages:</i></b> Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019.

Publisher

S. Karger AG

Subject

Oncology,Hepatology

Reference178 articles.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108.

2. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2019 Sep 28;394(10204):1145–58.

3. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004 Jul;130(7):417–22.

4. Dong Y, Wang WP, Mao F, Ji ZB, Huang BJ. Application of imaging fusion combining contrast-enhanced ultrasound and magnetic resonance imaging in detection of hepatic cellular carcinomas undetectable by conventional ultrasound. J Gastroenterol Hepatol. 2016 Apr;31(4):822–8.

5. da Silva NPB, Hornung M, Beyer LP, Hackl C, Brunner S, Schlitt HJ, et al. Intraoperative shear wave elastography vs. contrast-enhanced ultrasound for the characterization and differentiation of focal liver lesions to optimize liver tumor surgery. Ultraschall Med. 2019 Apr;40(2):205–11.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3